Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.0010 USD
Change Today 0.00 / 0.00%
Volume 0.0
MRVT On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 05/18/15 All times are local (Market data is delayed by at least 15 minutes).

miravant medical technologie (MRVT) Snapshot

Open
$0.0010
Previous Close
$0.0010
Day High
$0.0010
Day Low
$0.0010
52 Week High
04/7/15 - $0.0010
52 Week Low
05/30/14 - $0.0001
Market Cap
37.9K
Average Volume 10 Days
200.0
EPS TTM
--
Shares Outstanding
37.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MIRAVANT MEDICAL TECHNOLOGIE (MRVT)

Related News

No related news articles were found.

miravant medical technologie (MRVT) Related Businessweek News

No Related Businessweek News Found

miravant medical technologie (MRVT) Details

Miravant Medical Technologies Inc. researches and develops drugs based on PhotoPoint technology that respond to light, destroying cancerous cells and leaving normal cells intact. It also manufactures light producing and light delivery devices. The company’s drugs when activated by light induce a photochemical reaction in the presence of oxygen that can be used to destroy diseased cells and abnormal blood vessels. Its drugs and devices are in various stages of development, which include PHOTREX, a phase III clinical trial product, to be used for the treatment of wet age-related macular degeneration or AMD; MV9411, a phase II clinical trial product, for the treatment of plaque psoriasis; and MV0633, an advanced preclinical stage product, to be used for the treatment of atherosclerosis, atherosclerotic vulnerable plaque, and restenosis. The company’s products also comprise MV2101, an advanced preclinical stage product, to be used for the treatment of vascular access graft disease in hemodialysis patients; and MV6401, a preclinical stage product, for the treatment of solid tumors. The company’s light technologies include software-controlled diode lasers, light emitting diode, or LED, arrays, and noncoherent light sources. The company has collaborative agreements with Kendle International, Inc.; Gilead Sciences, Inc.; Iridex Corporation; and Guidant Corporation for the development of its products. Miravant Medical Technologies Inc. was formerly known as PDT, Inc. and changed its name to Miravant Medical Technologies Inc. in September, 1997. Miravant Medical Technologies Inc. was founded in 1989 and is headquartered in Santa Barbara, California.

47 Employees
Last Reported Date: 03/29/05
Founded in 1989

miravant medical technologie (MRVT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRVT:US $0.00 USD 0.00

MRVT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MRVT.
View Industry Companies
 

Industry Analysis

MRVT

Industry Average

Valuation MRVT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MIRAVANT MEDICAL TECHNOLOGIE, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.